OncoCyte (NASDAQ:OCX) Releases Quarterly Earnings Results
OncoCyte (NASDAQ:OCX) reported quarterly earnings of ($0.26) EPS, with a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The stock fell 2.1% to $2.81, with a market cap of $80.36 million. Analysts have mixed ratings, with StockNews.com issuing a "sell" rating, while Lake Street Capital set a "buy" rating with a $5.00 price target. OncoCyte focuses on precision diagnostics and is developing several proprietary tests for cancer treatment monitoring.
OncoCyte (NASDAQ:OCX - Get Free Report) posted its earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, Zacks reports. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%.
OncoCyte Stock Down 2.1%
NASDAQ:OCX traded down $0.06 during mid-day trading on Monday, hitting $2.81. 64,472 shares of the stock traded hands, compared to its average volume of 57,484. The business's 50-day moving average price is $3.17 and its 200 day moving average price is $2.70. The company has a market cap of $80.36 million, a PE ratio of -0.64 and a beta of 0.95. OncoCyte has a 12-month low of $1.92 and a 12-month high of $4.75.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on OCX shares. StockNews.com started coverage on shares of OncoCyte in a research note on Sunday, April 6th. They issued a "sell" rating for the company. Lake Street Capital began coverage on shares of OncoCyte in a research note on Friday, March 28th. They set a "buy" rating and a $5.00 price objective for the company. Stephens reaffirmed an "equal weight" rating and set a $4.00 price objective on shares of OncoCyte in a research note on Tuesday, March 25th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a research note on Tuesday, April 8th.
Check Out Our Latest Stock Analysis on OncoCyte
OncoCyte Company Profile
(Get Free Report)OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Read More
- Five stocks we like better than OncoCyte
- What Are Earnings Reports?
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- Most active stocks: Dollar volume vs share volume
- Here's Why Call Option Traders Love Dutch Bros Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in OncoCyte Right Now?
Before you consider OncoCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.
While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
